St.Vincent's HEALTH SYSTEM		CE/CME Evaluation & Credit Claim Form			Enduring		
		TITLE OF AC	TIVITY:	Credits: 1.00			
		"Non-Smal	l Cell Lung Cancer	□ Direct Sponsored			
Date:		Therapy an	nd Beyond"		☐ Jointly Sponsored		
Please Check One:	St. Vincent'	s Birmingham	St. Vincent's Blo	ent's Chilton			
	St. Vincent	's East	St. Vincent's St. Clair	St. Vincent's	One Nineteen		
☐ External Meeting							
St. Vincent's Health System is committed to excellence in continuing education and your opinions are critical to us in this effort.							
Please note:	a CME/CE certific	ate is issued or	nly upon receipt of thi	is <mark>completed</mark> evalu	ation form. PLEASE PRINT		
Legal Name:				Email Address: (This is where your CE/CME certificate an or transcriptwill be ser			
Identify which	□MD	□ DO	□PA	Ministry and			
continuing	□ NP	□RN		Facility:			
education hours apply to you:	☐ PharmD	□ RPh	□ Tech	Pharmacists			
арріу со уоц.	□ ОТ	$\Box PT$	□Social Worker	please enter you	r		
	□Student	□Other		NABP # & DOB			
Comments on this Enduring Material:							

**Method of Participation** - To receive a maximum of  $1.0 \ Credit(s)$  you should:

- View the materials in this enduring material.
- Complete the posttest (you must answer 4 out of 5 questions correctly).
- Complete and submit the CME/CE registration and evaluation forms.

The estimated time to complete this activity, including review of the materials, is 1.0 hour(s).

**Statement of Evaluation Instrument:** The activity post- test and evaluation instrument are required for credit. Learners must earn a 75% correct rate on the post-test to receive credit.

- 1. What would you recommend for a patient with nonsquamous NSCLC and low PD-L1 expression who progressed 4 months after completing first-line treatment with Carbo/Pemetrexed/Pembrolizumab, while receiving Pembrolizumab/Pemetrexed maintenance?
  - a) Switch to different immune checkpoint inhibitor and chemotherapy
  - b) Rechallenge platinum-based chemotherapy ± Bevacizumab
  - c) Continue Pembrolizumab and switch chemotherapy
  - d) Docetaxel + Ramucirumab
  - e) Docetaxel
- 2. During advanced NSCLS you determine current treatment landscape for performance status, histology, presence of driver mutations, PD-L1 expression.
  - a) True
  - b) False

therapy:		

3. Name two factors that impact treatment selection for patients who have progressive disease after first-line

- 4. During immune related adverse events it is important for early recognition/management and to educate patients and all the healthcare team.
  - a. True
  - b. False
- 5. Immunotherapy is taking central stage in the management of advanced NSCLC.
  - a. True
  - b. False

Please scan back for credit to: <a href="lisa.davis2@ascension.org">lisa.davis2@ascension.org</a>
Phone: (205) 838-3225 Fax: (205) 838-3518

**Copyright © 2012, St. Vincent's Health System.** All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from STVHS.

ASCENSION Stillingents	Attendance F	Roster	Instructor: Rathi Pillai, M.D.						
HEALTH SYSTEM	"Lung Cancor Soco	and Line	Cancer Institute						
JOINTLY ACCREDITED PROVIDER" INTERPROFESSIONAL CONTINUING EDUCATION	"Lung Cancer – Seco Therapy and Beyond		Credits: 1.0						
	Therapy and beyond								
☐ Direct Sponsored ☐ Jointly Sponsored	Date:		OUTSIDE ACTIVITY						
Please Check One: St. Vincent's Hea	alth (Bham)								
			er:						
		/51							
Name <mark>(Please Print)</mark>	Hospital/Ministry/ (Pharm DOB & N								
	Business	DOD & IVAD							
			│						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			☐MD ☐ DO ☐ NP ☐ PA						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			MD						
			RN Pharmacist RPh						
			☐ Pharmacy Tech ☐ OT ☐ PT ☐ Social Worker ☐ Student ☐ Other						
			MD DO NP PA						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			MD DO NP PA						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			☐MD ☐ DO ☐ NP ☐ PA						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			☐MD ☐ DO ☐ NP ☐ PA						
			RN Pharmacist RPh						
			☐Pharmacy Tech ☐OT ☐ PT						
			Social Worker Student Other						
			☐MD ☐ DO ☐ NP ☐ PA						
			RN Pharmacist RPh						
			☐ Pharmacy Tech ☐ OT ☐ PT						
In curport of improving a	ationt care Assension/St	· Vincont's Ha	Social Worker Student Other  alth is jointly accredited by the						
			i), the Accreditation Council for						
			tialing Center (ANCC), to provide						
iPCE CREDIT™ continuing education for t			g 55.115. (, 11155), to provide						
			4.0 IDOF						
This activity was planned by and for the healthcare team, and learners will receive 1.0 IPCE credits for learning and									
change.									
Faculty/Course Director/Planners: ST	VHS has selected all faculty po	articinating in this	activity. It is the policy of STVHS that all CME/CE						
planning committees, faculty, authors, editors, and s									
Disclosure documents are reviewed for potential corparticipants who have no conflict of interest or who a	oflicts of interest and if relevant	t, they are resolved	d prior to confirmation of participation. Only those						



## **EVALUATION FORM**

Post-Platinum Therapeutic Options in Advanced Non-Small Cell Lung Cancer Tuesday, August 14, 2018 – Birmingham, Alabama Project ID: PI8LCR018

prIME Oncology is committed to excellence in continuing education, and your opinions are critical in this effort. To assist us in evaluating the effectiveness of this activity and planning future educational offerings, please take a few minutes to complete this evaluation form. All responses are confidential.

Shade in bubbles =

What is your profe ○ Physician ○		O Nurs oner	se O Ph	armacist(	Other healtho		) Nonclinica
What is your pract  Community	_	nclinical					
How many patient	s in this therapeutic at 21-40 41-6	area do you s 0 O 6	<b>ee each w</b> 61-80	eek?	. 0	Not applica	able
Please rank the overall quality of this activity.  Great Good Neutral  (5) (4) (3)			Poor Very Poor (2) (1)				or
Please rate vour lev	rel of agreement by ma	arking the appr	opriate rati	na			
	,	ariang are appr	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
This activity met t	he stated educational	objectives.	(5)	4	(3)	2	1
This activity conta practice.	ined content relevant	to my	(5)	4	3	2	1
Presenter(s) was/were knowledgeable and effective.			5	4	(3)	(2)	(1)
This activity increased my likelihood to change management strategies in this therapeutic area within the next six months.				4	3	2	1
As a result of atten	ding this educationa ommitted to making.	l activity, plea	ase list on	e or two s	pecific ch	anges in y	our
	nal activity fair, balan	ced, and free	of comme	rcial bias?	? If no, ple	ease elabo	rate.
O Yes							
U INO							
Are there any spec would like further e	ific barriers to practi education?	ce associated	with this	therapeuti	c area foi	which yo	u
Please provide any	additional comment	s or feedback	:		7		

<b>Prior</b> to the educational activity	1: Not Confident	1: Not Confident 2: Confident 3: Very Conf		dent	l l	After the educational activity		
1 2 3	Please rank yoυ	ır co	onfidence in treat area	ing this thera	peutio	C (1)	2	3
Select the national qu	ality strategy pri	oriti	ies this prograr	n addressed.	. (Sel	ect all tha	t apply	)
O Safer care	O Effective communication	n	O Coordina	tion of care	C	D Effective practice		nent
Select the barriers to	Select the barriers to optimal patient care this program addressed. (Select all that apply)							
<ul><li>Conflicting evice</li></ul>	dence (	$\mathcal{C}$	Cost of therapy		0	Patient ad	herence	)
O Clinical trial access		) L	Lack of training			Patient knowledge		
Select the quality com	ponents this pro	gra	ım addressed. (	Select all tha	ıt apı	ply)		
O Shared decisio	n making (	) (	Care manageme	nt	0	Communic	ation	
O Patient educati	on (	T C	reatment expec	tations	0	Care trans	ition	
O Cross-provider coordination								
To claim your certificate, please provide your email below, and a certificate link will be e-mailed to you:								
Email:								
			@			·		